Nanocarriers as phototherapeutic drug delivery system: Appraisal of three different nanosystems in an in vivo and in vitro exploratory study

Ricci-Júnior, Eduardo; Siqueira, Luciana de Oliveira de Betzler; Schuenck-Rodrigues, Raphaela Aparecida; Sancenón, Félix; Martínez‐Máñez, Ramón; Moraes, João Alfredo; Santos-Oliveira, Ralph

doi:10.1016/j.pdpdt.2017.11.003

Cited by 16 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ZnPc molecules have been also encapsulated into NPs of different nature, such as polymeric NPs (Conte et al, 2013;Ping et Huang et al, 2016), TiO2 NPs (Yurt et al, 2017;Lopez et al, 2010), gold NPs (Camerin et al, 2010Manoto et al, 2017a;Mfouo-Tynga et al, 2018aDube et al, 2018;Garcia Vior et al, 2019) and silica based NPs (Tu et al, 2012;Oluwole et al, 2016). Ricci-Junior et al (2018), after evaluating the photobiological activity of three nanosystems (nanoparticles, nanoemulsions and mesoporous silica) containing ZnPc, demonstrated that all of these formulations could be used for clinical purposes in PDT. Furthermore, upconverting nanoparticles (UCNPs), based on the absorption and conversion of near infrared light to visible photons that can further activate the PS, have been efficiently employed as PDT carriers for ZnPcs (Guo et al, 2010;Tian et al, 2013;Wang H. et al, 2014a;Hou et al, 2015).…”

Section: Third Generation Zinc(ii) Phthalocyaninesmentioning

confidence: 99%

Zinc(II) phthalocyanines as photosensitizers for antitumor photodynamic therapy

Roguin

Chiarante

Vior

et al. 2019

The International Journal of Biochemistry & Cell Biology

109

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a highly specific and clinically approved method for cancer treatment in which a nontoxic drug known as photosensitizer (PS) is administered to a patient. After selective tumor irradiation, an almost complete eradication of the tumor can be reached as a consequence of reactive oxygen species (ROS) generation, which not only damage tumor cells, but also lead to tumor-associated vasculature occlusion and the induction of an immune response. Despite exhaustive investigation and encouraging results, zinc(II) phthalocyanines (ZnPcs) have not been approved as PSs for clinical use yet. This review presents an overview on the physicochemical properties of ZnPcs and biological results obtained both in vitro and in more complex models, such as 3D cell cultures, chicken chorioallantoic membranes and tumor-bearing mice. Cell death pathways induced after PDT treatment with ZnPcs are discussed in each case. Finally, combined therapeutic strategies including ZnPcs and the currently available clinical trials are mentioned.

show abstract

Section: Third Generation Zinc(ii) Phthalocyaninesmentioning

confidence: 99%

Zinc(II) phthalocyanines as photosensitizers for antitumor photodynamic therapy

Roguin

Chiarante

Vior

et al. 2019

The International Journal of Biochemistry & Cell Biology

109

View full text Add to dashboard Cite

show abstract

“…The strategies that has been developed and applied for years in nanosystems can be used and coupled with the ones that aim to modulate the ABC efflux function, enhancing the efficacy of today's formulations (e.g., all generations of ABC inhibitors) that still holds many issues as described before [46]. Graphene [55,56], silica mesoporous [57] and polymeric nanoparticles [58] are promising vehicles that can be built with high specificity to tumor cells, fulfilling these strategies [46].…”

Section: Nanosystemsmentioning

confidence: 99%

The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein

Mello

Moraes

Maia

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

The cancer multidrug resistance is involved in the failure of several treatments during cancer treatment. It is a phenomenon that has been receiving great attention in the last years due to the sheer amount of mechanisms discovered and involved in the process of resistance which hinders the effectiveness of many anti-cancer drugs. Among the mechanisms involved in the multidrug resistance, the participation of ATP-binding cassette (ABC) transporters is the main one. The ABC transporters are a group of plasma membrane and intracellular organelle proteins involved in the process of externalization of substrates from cells, which are expressed in cancer. They are involved in the clearance of intracellular metabolites as ions, hormones, lipids and other small molecules from the cell, affecting directly and indirectly drug absorption, distribution, metabolism and excretion. Other mechanisms responsible for resistance are the signaling pathways and the anti- and pro-apoptotic proteins involved in cell death by apoptosis. In this study we evaluated the influence of three nanosystem (Graphene Quantum Dots (GQDs), mesoporous silica (MSN) and poly-lactic nanoparticles (PLA)) in the main mechanism related to the cancer multidrug resistance such as the Multidrug Resistance Protein-1 and P-glycoprotein. We also evaluated this influence in a group of proteins involved in the apoptosis-related resistance including cIAP-1, XIAP, Bcl-2, BAK and Survivin proteins. Last, colonogenic and MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) assays have also been performed. The results showed, regardless of the concentration used, GQDs, MSN and PLA were not cytotoxic to MDA-MB-231 cells and showed no impairment in the colony formation capacity. In addition, it has been observed that P-gp membrane expression was not significantly altered by any of the three nanomaterials. The results suggest that GQDs nanoparticles would be suitable for the delivery of other multidrug resistance protein 1 (MRP1) substrate drugs that bind to the transporter at the same binding pocket, while MSN can strongly inhibit doxorubicin efflux by MRP1. On the other hand, PLA showed moderate inhibition of doxorubicin efflux by MRP1 suggesting that this nanomaterial can also be useful to treat MDR (Multidrug resistance) due to MRP1 overexpression.

show abstract

“…Photodynamic therapy (PDT) acts by a production of reactive oxygen species (ROS) using a photosensitizer molecule in the presence of low-intensity visible light to promote cell death [29,[37][38][39]. This therapy is non-invasive, does not affect intact skin around the lesions [37,40].…”

Section: Introductionmentioning

confidence: 99%

“…This therapy is non-invasive, does not affect intact skin around the lesions [37,40]. Porphyrins precursors, specially 5-aminolevulinic acid (ALA) or methyl-aminolevulinic acid (MAL), and phthalocyanines are often used as photosensitizers with visible red light (633 nm) application [29,38,40]. PDT requires special medical equipment and repeatable applications [40].…”

Section: Introductionmentioning

confidence: 99%

A review of current treatments strategies based on paromomycin for leishmaniasis

Matos

Viçosa

Ré

et al. 2020

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Leishmaniasis is a neglected disease caused by protozoan parasites of the Leishmania genus, which affects many people in several countries. This disease has three major clinical forms: cutaneous, mucocutaneous and visceral. The current treatments consist of an intravenous, intralesional or intramuscular administration of pentavalent antimonials, but other drugs can be used, among them, amphotericin B, pentamidine, paromomycin and miltefosine. However, these therapies have many side effects. Hence, there is an increase of studies searching for new formulations using different technologies and different routes of administration for leishmaniasis treatment. Paromomycin sulfate (PM) is an aminoglycoside antibiotic, belonging to class III of biopharmaceutical classification system, used intravenously and topically with leishmanicidal activity. This review will provide a general overview of PM current leishmaniasis treatments and new PM formulations. Treatments using PM are available in ointments or creams for topical administration and PM solution for intramuscular administration. The topical treatment with PM presents low efficacy, probably related to low drug permeability across the skin. To improve PM permeability and efficacy, researchers are establishing micro and nanotechnologies. However, further studies are still required to investigate more physicochemical properties and in vitro/in vivo parameters.

show abstract

Nanocarriers as phototherapeutic drug delivery system: Appraisal of three different nanosystems in an in vivo and in vitro exploratory study

Cited by 16 publications

References 18 publications

Zinc(II) phthalocyanines as photosensitizers for antitumor photodynamic therapy

Zinc(II) phthalocyanines as photosensitizers for antitumor photodynamic therapy

The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein

A review of current treatments strategies based on paromomycin for leishmaniasis

Contact Info

Product

Resources

About